Altre lingue Kadimastem Ltd

Azioni

KDST

IL0011284614

Mercato chiuso - TEL AVIV STOCK EXCHANGE Altri mercati azionari 16:24:36 04/07/2024			Variaz. 5gg	Var. 1 gen.
498,1 ^ILa	+0,89%		+3,77%	-16,00%

28/03	Kadimastem Ltd riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
28/02	IMC annuncia una potenziale fusione inversa con un'azienda leader di terapia cellulare clinica	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market	28/05
Kadimastem Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	28/02
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC	28/02
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company	28/02
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	28/02
Kadimastem Plans Listing on Nasdaq Through Merger	18/02
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq	16/02
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India	07/02
A peer reviewed article on Kadimastem's AstroRxÃ‚® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology	25/01
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA	22/01
ITolerance, Inc. and Kadimastem Ltd. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products	07/11
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes	07/11
Kadimastem Ltd announced that it expects to receive ILS 6.783 million in funding from Alpha Capital Anstalt and another investor	16/10/23
Kadimastem Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes	20/06/23
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS	09/03/21
Kadimastem : Announces Executive Management Changes	01/02/21
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial	16/12/20
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS	03/08/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kadimastem Ltd

Azioni

KDST

IL0011284614

Altre lingue

Filtri